This review highlights the role of lipid nanocarriers in enhancing therapeutic efficacy for rheumatoid arthritis, suggesting targeted drug delivery can improve patient outcomes.
Key Points
Targeted drug delivery using lipid nanocarriers improves therapeutic efficacy for rheumatoid arthritis.
The review emphasizes niosomes, which enhance bioavailability and minimize systemic side effects.
Current rheumatoid arthritis therapies face limitations, indicating a need for innovative drug delivery systems.
Understanding immune cell interactions in rheumatoid arthritis is crucial for developing personalized treatments.